Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019.
History
In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.[1]
In November 2000, the company became a public company via an initial public offering.[2]
In June 2019, Pfizer acquired the company for approximately $11 billion.[3]
Discovery of FDA Approved Small Molecules
- MEKTOVI (Binimetinib) – selective MEK inhibitor – Approved 2018, acquired by Pfizer
- TUKYSA (Tucatinib) – HER2 inhibitor – Approved 2020, owned by Seagen (Seattle Genetics)
- BRAFTOVI (Encorafenib) – BRAF inhibitor – Approved 2018, acquired by Pfizer
- KRAZATI (Adagrasib) – KRasG12C mutation inhibitor – Approved 2022, collaboration with Mirati Therapeutics
- KOSELUGO (Selumetinib) – MEK1/2 inhibitor – Approved 2020, licensed by Astrazeneca
- VITRAKVI (Larotrectinib) – TRK Inhibitor – Approved 2018, licensed by Loxo Oncology (Eli Lilly)
- RETEVMO (Selpercatinib) – RET inhibitor – Approved 2024, licensed by Loxo Oncology (Eli Lilly)
- GANOVO (Danoprevir) – HCV Protease inhibitor – Approved 2018 (in China), licensed by Roche
References
- ^ “Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company”. BioSpace. Retrieved 2020-07-28.
- ^ “Array IPO up 17%”. CNN. November 17, 2000.
- ^ “Pfizer acquires Array BioPharma, valued at $11.4 billion”. Rappler. 18 June 2019. Retrieved 2020-07-29.
